Organovo (NASDAQ:ONVO – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $0.05 million for the quarter.
Organovo Price Performance
Shares of ONVO opened at $0.35 on Wednesday. Organovo has a 1-year low of $0.32 and a 1-year high of $1.74. The company has a market capitalization of $5.32 million, a P/E ratio of -0.33 and a beta of 0.54. The firm’s 50 day simple moving average is $0.39 and its 200 day simple moving average is $0.46.
Analyst Ratings Changes
Separately, StockNews.com began coverage on shares of Organovo in a report on Friday, February 7th. They set a “sell” rating for the company.
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
See Also
- Five stocks we like better than Organovo
- Quiet Period Expirations Explained
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- Using the MarketBeat Stock Split Calculator
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- Profitably Trade Stocks at 52-Week Highs
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
